惠州吉星互动传媒有限公司

中国建材股份有限公司

中国建材集团有限公司（简称中国建材集团）是经国务院批准，由中国建筑材料集团有限公司与中国中材集团有限公司重组而成，是国务院国有资产监督管理委员会直接管理的中央企业。
中国建材集团是全球最大的综合性建材产业集团、世界领先的新材料开发商和综合服务商，连续12年荣登《财富》世界500强企业榜单，2022年排名196位。截至2022年底，资产总额6800多亿元，年营业收入3800多亿元，员工总数20万人。拥有14家上市公司，其中境外上市公司2家。水泥、商混、石膏板、玻璃纤维、风电叶片、水泥玻璃工程技术服务等7项业务规模居世界第一；超薄电子玻璃、高性能碳纤维、锂电池隔膜、超特高压电瓷等多项新材料业务国内领先。
中国建材集团是一家科技型企业，在我国建筑材料与无机非金属新材料领域拥有最雄厚的科研实力，拥有3.8万名科技研发和工程技术人员，26家国家级科研设计院所，有效专利2.1万项，55个国家、行业质检中心和行业最权威检验认证机构，11个国家重点实验室和工程（技术）研究中心，19个国家标委会，7项国家科技进步一等奖，4项中国工业大奖。
中国建材集团是一家国际化公司，是我国建材行业“走出去”参与“一带一路”建设的排头兵，水泥玻璃工程国际市场占有率达65%，在德国、印度、蒙古国及非洲国家进行投资布局，正向世界建材舞台的中央迈进。
中国建材集团正式转为国有资本投资公司，按照“4335”指导原则，加快推进管企业向管资本、建筑材料向综合材料、 本土市场向全球布局“三大转变”，持续增强集团的竞争力、创新力、控制力、影响力、抗风险能力，加快培育具有全球竞争力的世界一流材料产业投资集团。

贵州飞腾凹服帮教育科技有限公司

贵州飞腾凹服帮教育科技有限公司，公司规模为少于50人，公司类型为民营公司，所属行业为教育/培训/院校。

上药康德乐(重庆)医药有限公司

SPH KDL Health (Chongqing) Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is a holding subsidiary of SPH Group, which is managed by the State-owned Assets Supervision and Administration Commission of Shanghai Municipality. The parent company, Shanghai Pharma Group, is a leading enterprise in the pharmaceutical industry in China. Its business covers the entire industrial chain of pharmaceutical research and development, manufacturing, distribution, retail, and investment. In 2020, it entered the list of the world's top 500 companies, ranking 473, and ranked 57 among the top 500 listed enterprises in China (A+H). It is also ranked 48th globally in the pharmaceutical industry, 24th globally in pharmaceutical brands, and among the top three in the Chinese pharmaceutical industry. In 2019, the company achieved an operating revenue of 186.6 billion yuan, ranking 43rd among the top 500 Chinese manufacturing enterprises, 93rd in the "China Brand Development Index" 100 list by the People's Daily, and 25th in global pharmaceutical brand value.

The Chongqing company was established in 1993, formerly known as Chongqing Pharmaceutical Development Company under the Chongqing Pharmaceutical Administration, with a registered capital of 50 million yuan, located at No. 137 Keyuan Second Road, Jiulongpo District, with 115 employees. The company is dedicated to diversified supply chain services such as drugs and medical devices and is a mainstream pharmaceutical circulation enterprise in Chongqing. It ranks second in the transaction and distribution amount of medical institutions in the Chongqing Drug Exchange. It is authorized by over a thousand manufacturers and can deliver more than 15,000 product specifications. The company is also the only national pharmaceutical circulation enterprise in Jiulongpo District and has been selected as one of the designated distribution members of the Jiulongpo District consortium for two consecutive terms, undertaking the security supply of nearly a thousand product specifications of medicines in 22 medical institutions in Jiulongpo District.

The company has received titles such as "Vice Chairman Unit of Chongqing Pharmaceutical Industry Association," "Vice Chairman Unit of Chongqing Medical Insurance Research Association," "Vice Chairman Unit of Chongqing Jiulongpo Pharmaceutical Chamber of Commerce," and "Jiulongpo District Model and Demonstration Wholesale Enterprise." It has been inspected and guided by the State Food and Drug Administration, district government, and district People's Congress multiple times.

In 2020, the company achieved an operating revenue of 1.56 billion yuan (including tax) and paid taxes of 16.69 million yuan. During the 2020 pandemic, the company was designated as a "Chongqing Epidemic Prevention Material Reserve Unit" and contributed positively to the city's fight against the epidemic, earning the title of "Special Contribution Enterprise for Epidemic Resistance."

The company will continue to rely on the strong headquarters resources of SPH Group, adhering to a customer-centric service philosophy, compliance, integrity, and transparent management requirements, to better fulfill its responsibilities in serving medical reform and society, safeguarding people's livelihood, and serving the vast number of patients in the area, making new contributions to the medical and health reform of Jiulongpo District.